ArticleBMC microbiology2026
Molecular characteristics of chromosome-mediated colistin resistance in carbapenem-resistant Pseudomonas aeruginosa isolates from a tertiary hospital in China.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the prevalence and underlying mechanisms of colistin resistance among 557 non-duplicate CRPA isolates collected from a tertiary hospital in Jiangxi, China, between 2021 and 2024.
methodsAntimicrobial susceptibility testing, whole-genome sequencing, bioinformatic analyses, site-directed mutagenesis, RT-qPCR and time-kill kinetics assay were performed to investigate the mechanisms of colistin resistance in CRPA.
resultsAmong the 557 CRPA isolates, colistin minimum inhibitory concentrations (MICs) ranged from 0.125 to 32 mg/L, with MIC50 and MIC90 values of 1/2 mg/L. Twenty‑three isolates (23/557, 4.1%) exhibited colistin resistance (ColR‑CRPA), all showing multidrug‑resistant phenotypes. The 23 ColR‑CRPA isolates displayed extensive genetic diversity, encompassing 20 sequence types, with only two potential nosocomial transmission clusters (ST235 and ST1236) identified. Mutations in two‑component systems (pmrAB, phoPQ, parRS, and cprRS), lipid A modification genes (arnBCADTEF, eptA/eptA2/eptC), efflux regulators, and oprD were ubiquitous. Thirteen distinct amino acid substitutions were identified in PmrAB and PhoPQ, among which PmrA L71R (19/23, 82.6%) and PmrB Y345H (22/23, 95.7%) were the most prevalent. Functional characterization of all thirteen substitutions revealed that only PmrA Q109K, PmrB L107P, and PhoQ V260G significantly contributed to colistin resistance. Introducing these substitutions into the colistin‑susceptible reference strain PAO1 increased MICs by 2–4 fold, whereas reversion of PmrA Q109K or PhoQ V260G in clinical isolates reduced MICs from 32 to 4 mg/L. RT‑qPCR analysis showed that these substitutions significantly upregulated arnB and pmrA expression (P < 0.0001). Time‑kill kinetics assays further confirmed the enhanced colistin tolerance conferred by these mutations.
conclusionsColistin resistance in CRPA remains uncommon but is mediated by complex networks of chromosomal mutations. These findings highlight the importance of continuous genomic surveillance and strict infection‑control measures to prevent the emergence and dissemination of colistin‑resistant CRPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.